Type 2 Diabetes Linked to Increased Risk for Parkinson s medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
/CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into.
Share this article
TORONTO, Feb. 4, 2021 /PRNewswire/ - Diamond Therapeutics Inc. (
Diamond ), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement with McGill University for the exclusive use of Dr. Gabriella Gobbi s groundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders.
The agreement provides Diamond with access to the technology, data and intellectual property developed by Dr. Gobbi and postdoctoral fellow Danilo De Gregorio, PharmD, Ph.D. and published in the Proceedings of the National Academy of Sciences of the United States of America. The work investigates for the first time the mechanism of action behind LSD s effect on social interactions. The findings suggest that psychedelics could play a role in treating diseases characterized by social impairment, such as autism spe